Raxar is a drug owned by Otsuka Pharmaceutical Co Ltd. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 08, 2013. Details of Raxar's patents and their expiration are given in the table below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
US5563138 | Benzoheterocyclic compounds |
Oct, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Raxar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Raxar's family patents as well as insights into ongoing legal events on those patents.
Raxar's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Raxar's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 08, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Raxar Generics:
There are no approved generic versions for Raxar as of now.
About Raxar
Raxar is a drug owned by Otsuka Pharmaceutical Co Ltd. Raxar uses Grepafloxacin Hydrochloride as an active ingredient. Raxar was launched by Otsuka in 1997.
Approval Date:
Raxar was approved by FDA for market use on 06 November, 1997.
Active Ingredient:
Raxar uses Grepafloxacin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Grepafloxacin Hydrochloride ingredient
Dosage:
Raxar is available in tablet form for oral use. Given below is detailed information on Dosage -
Strength | Dosage Form | Availability | Application Pathway |
---|---|---|---|
EQ 200MG BASE | TABLET | Discontinued | ORAL |